RecruitingPhase 2NCT06259721

Anti-PD1 Monoclonal Antibody Combined With Nimotuzumab and Capecitabine in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma

Studying Nasopharyngeal carcinoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Jiangxi Provincial Cancer Hospital
Principal Investigator
Jingao Li, MD
NHC Key Laboratory of Personalized Diagnosis and Treatment of Nasopharyngeal Carcinoma, Jiangxi Cancer Hospital
Intervention
Anti-PD1 antibody, nimotuzumab and capecitabine(drug)
Enrollment
22 target
Eligibility
18-70 years · All sexes
Timeline
2024 – 2026

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06259721 on ClinicalTrials.gov

Other trials for Nasopharyngeal carcinoma

Additional recruiting or active studies for the same condition.

See all trials for Nasopharyngeal carcinoma →

← Back to all trials